PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

BIOCRYST US SALES CO., LLC

BIOCRYST US SALES CO., LLC reported $656.6K in payments to physicians and teaching hospitals across 6,386 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for BIOCRYST US SALES CO., LLC. Ranked #666 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$656.6K

0.0% of all payments

Transactions

6,386

$102.81 avg

Recipients

6,386

$102.81 avg

Industry Rank

#666

of 1,797 companies

What the Data Shows for BIOCRYST US SALES CO., LLC

In Program Year 2024, BIOCRYST US SALES CO., LLC reported $656,568.65 in payments to 6,386 physicians and teaching hospitals across 6,386 individual transactions — an average of $102.81 per transaction and $102.81 per recipient. That total places BIOCRYST US SALES CO., LLC at rank #666 out of 1,797 companies in the CMS Open Payments database, representing 0.0% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for BIOCRYST US SALES CO., LLC spans 7 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Compensation for Services Other Than Consulting" at $294.9K, accounting for 44.9% of the company's reported total and 86 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from BIOCRYST US SALES CO., LLC received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 6,386 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

BIOCRYST US SALES CO., LLC made 7 types of payments. "Compensation for Services Other Than Consulting" accounts for 44.9%.

Compensation for Services Other Than Consulting $294.9K

44.9% · 86 transactions

Food and Beverage $154.2K

23.5% · 6,092 transactions

Consulting Fee $118.3K

18.0% · 33 transactions

Travel and Lodging $49.7K

7.6% · 117 transactions

Grant $29.7K

4.5% · 3 transactions

Space Rental or Facility Fees $9.1K

1.4% · 6 transactions

Education $607.99

0.1% · 49 transactions

Payment Type Amount Transactions
Compensation for Services Other Than Consulting $294.9K 86
Food and Beverage $154.2K 6,092
Consulting Fee $118.3K 33
Travel and Lodging $49.7K 117
Grant $29.7K 3
Space Rental or Facility Fees $9.1K 6
Education $607.99 49

Payment Size Analysis

Average transaction size: $102.81. Average per recipient: $102.81.

Total Amount

$656,568.65

Avg per Transaction

$102.81

Avg per Recipient

$102.81

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

BIOCRYST US SALES CO., LLC Share

0.0%

#666 by total payments

Frequently Asked Questions

How much did BIOCRYST US SALES CO., LLC pay to physicians and hospitals in 2024?
BIOCRYST US SALES CO., LLC made $656,568.65 in payments to physicians and hospitals in Program Year 2024, across 6,386 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from BIOCRYST US SALES CO., LLC?
BIOCRYST US SALES CO., LLC made payments to 6,386 physicians and teaching hospitals in 2024. The average payment per recipient was $102.81.
What types of payments did BIOCRYST US SALES CO., LLC make?
BIOCRYST US SALES CO., LLC made 7 different types of payments. The largest category was "Compensation for Services Other Than Consulting" at $294.9K, representing 44.9% of all payments.
How does BIOCRYST US SALES CO., LLC rank among pharmaceutical companies?
BIOCRYST US SALES CO., LLC ranks #666 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from BIOCRYST US SALES CO., LLC?
The average transaction from BIOCRYST US SALES CO., LLC was $102.81 in 2024. The company made 6,386 total transactions to 6,386 recipients.
Are the top recipients concentrated for BIOCRYST US SALES CO., LLC?
The top 5 recipients received $0.00 from BIOCRYST US SALES CO., LLC, representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for BIOCRYST US SALES CO., LLC come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.